Y-mAbs Therapeutics, Inc. (YMAB)

Market Cap	391.22M
Revenue (ttm)	85.39M
Net Income (ttm)	-22.22M
Shares Out	45.44M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	760,675
Open	8.59
Previous Close	8.59
Day's Range	8.59 - 8.61
52-Week Range	3.55 - 16.11
Beta	0.53
Analysts	Buy
Price Target	13.91 (+61.56%)
Earnings Date	Nov 7, 2025

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 21, 2018
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: YMAB
• Website: https://www.ymabs.com

Financial Performance

In 2024, Y-mAbs Therapeutics's revenue was $87.69 million, an increase of 3.38% compared to the previous year's $84.82 million. Losses were -$29.67 million, 38.5% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price target is $13.91, which is an increase of 61.56% from the latest price.

Price Target

$13.91

(61.56% upside)

Analyst Consensus: Buy